Vincent Mikol

Sanofi R&D
Vitry-sur-seine, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

A phase 2 trial of rilzabrutinib in IgG4-related disease.

A phase 2 trial of rilzabrutinib in IgG4-related disease.

Journal: Annals of the rheumatic diseases

Published: February 03, 2026

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study.

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study.

Journal: The Lancet. Respiratory medicine

Published: September 15, 2025

Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.

Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.

Journal: JAMA dermatology

Published: April 23, 2025

Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial.

Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial.

Journal: The British journal of dermatology

Published: November 19, 2024

Atuzabrutinib Topical Gel Does Not Improve Disease Activity in Patients with Mild-to-Moderate Atopic Dermatitis: Findings from a Phase 2A Trial.

Atuzabrutinib Topical Gel Does Not Improve Disease Activity in Patients with Mild-to-Moderate Atopic Dermatitis: Findings from a Phase 2A Trial.

Journal: The Journal of investigative dermatology

Published: September 10, 2024

2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 - Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization.

2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 - Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization.

Journal: Bioanalysis

Published: August 16, 2023

A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.

A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.

Journal: Nature medicine

Published: April 18, 2019

Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.

Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.

Journal: JCI insight

Published: December 19, 2017

CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.

CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.

Journal: mAbs

Published: March 18, 2016

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium.

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium.

Journal: Clinical and experimental immunology

Published: March 23, 2015

Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents.

Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents.

Journal: Scientific reports

Published: August 22, 2014

Engineering protein therapeutics: predictive performances of a structure-based virtual affinity maturation protocol.

Engineering protein therapeutics: predictive performances of a structure-based virtual affinity maturation protocol.

Journal: Journal of chemical information and modeling

Published: July 14, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026